The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Addressing unmet needs in patients with lung cancer
Nathan Pennell, MD, PhD, Cleveland Clinic, Cleveland, OH, gives an overview of remaining challenges in treating non-small cell lung cancer (NSCLC). Patients whose tumors do not express CTLA-4 or PD-L1 may benefit less from current immunotherapies and many patients still have poor survival outcomes as a result. Novel targeted therapies will be crucial for these patients and Prof. Pennell highlights ongoing trials that assess concurrent immunotherapy and chemoradiotherapy in earlier stages of lung cancer as well as neoadjuvant and adjuvant therapy in surgically resectable lung cancer. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
